ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in New York, NY

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Recurrence
Cancer
Hematologic Cancer
Non-Hodgkin Lymphoma
Lymphoma
Leukemia

Multiple Myeloma trials near New York, NY, USA:

Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma

multicenter, dose-escalation study of STI-6129 administered intravenously once in a 4-week cycle in subjects with relapsed or refractory multiple...

Active, not recruiting
Multiple Myeloma
Biological: STI-6129

Phase 1, Phase 2

Sorrento Therapeutics
Sorrento Therapeutics

New York, New York, United States and 2 other locations

is an effective treatment for people with relapsed/refractory multiple myeloma (MM) who have risk factors that may affect how well ...

Enrolling
Multiple Myeloma
Biological: Elranatamab-bcmm
Drug: Cyclophosphamide

Phase 2

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

New York, New York, United States and 6 other locations

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.

Active, not recruiting
Multiple Myeloma
Drug: Isatuximab
Drug: CC-92480

Phase 1, Phase 2

Celgene
Celgene

Hackensack, New Jersey, United States and 48 other locations

The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma...

Enrolling
Relapsed or Refractory Multiple Myeloma
Drug: mRNA-2808

Phase 1, Phase 2

Moderna
Moderna

New York, New York, United States and 9 other locations

The purpose of this study is to assess the safety, tolerability, preliminary efficacy, cellular kinetics, and other exploratory endpoints of AZD4045...

Enrolling
Relapsed or Refractory Multiple Myeloma
Drug: Aldesleukin
Biological: AZD4045

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Hackensack, New Jersey, United States and 11 other locations

study to find out whether combining teclistamab and mezigdomide is a safe and effective treatment approach in people with relapsed/refractory multiple...

Enrolling
Multiple Myeloma
Drug: Teclistamab
Drug: Mezigdomide

Phase 1

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

New York, New York, United States and 6 other locations

characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with relapsed/refractory multiple...

Enrolling
Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
Drug: Cemsidomide
Drug: Dexamethasone

Phase 2

C4 Therapeutics

New York, New York, United States and 20 other locations

is a Phase 1b/2, open-label, multicenter study of AZD0120, a CD19/BCMA dual CAR T-cell therapy, in adult subjects with relapsed/refractory multiple...

Enrolling
Relapsed/Refractory Multiple Myeloma
Biological: AZD0120

Phase 1, Phase 2

AstraZeneca
AstraZeneca

New York, New York, United States and 35 other locations

this study will be to assess the efficacy and safety of treating elderly patients with relapsed/refractory multiple myeloma with a...

Enrolling
Multiple Myeloma in Relapse
Drug: Talquetamab
Drug: Daratumumab

Phase 2

Larysa Sanchez

New York, New York, United States

of these combinations in participants with relapsed or refractory multiple myeloma. The study will consist of 3 distinct parts: Par ...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab
Drug: Bortezomib

Phase 2

AbbVie
AbbVie

New York, New York, United States and 40 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems